Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 DWTX | Healthcare | $1.11 | 74.65K | $42.43M | -1.25 | ― | Moderate Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| DWTX | Dogwood Therapeutics | 1.11 | -4.46 | -80.07% |
| Name | Price | % Change | |
|---|---|---|---|
| DWTX | $1.11 | -80.07% |
Analyst Sean Lee CFA of H.C. Wainwright reiterated a Buy rating on Dogwood Therapeutics, with a price target of $12.00. Sean Lee CFA’s rating is based on several factors, led
This filing relates to the offer and sale from time to time by the selling stockholders of up to 4.1M shares of common stock. The company is not selling any
The latest announcement is out from Dogwood Therapeutics ( ($DWTX) ). On October 19, 2026, Dogwood Therapeutics entered into a subscription agreement for a $5 million private placement with its
Dogwood (DWTX) Therapeutics announced that the company has entered into a securities subscription agreement for a $5M investment from the company’s largest shareholder, a subsidiary of CK Life Sciences. The
Dogwood (DWTX) announced the completion of patient enrollment in its ongoing Halneuron Phase 2b Chemotherapy Induced Neuropathic Pain trial. The company anticipates topline data readout of the study in November.
Dogwood (DWTX) announced it has enrolled the first 200 patients in its ongoing HAL-CINP Phase 2b trial. HAL-CINP remains on track for top-line data readout from the four-week study in
Dogwood Therapeutics ( ($DWTX) ) has provided an update. On June 16, 2026, Dogwood Therapeutics, Inc. held its annual meeting of stockholders, where 95.17% of the company’s common stock voting
Dogwood (DWTX) Therapeutics announced commencement of a new Halneuron chemotherapy induced neuropathic pain phase 2b extension study. “Neuropathic pain is a difficult to treat chronic condition, as evidenced by the
Dogwood (DWTX) announced a global development and commercialization partnership with PRIDCor Therapeutics, a clinical-stage biopharmaceutical company developing antiviral therapies for infection-associated chronic illnesses including Long-COVID, for Dogwood’s anti-viral candidates, IMC-1
Dogwood (DWTX) announced FDA acceptance of an investigational new drug application for its development candidate SP16, administered intravenously, for the treatment of chemotherapy-induced pain and peripheral neuropathy. Published first on
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| DWTX | Apr 5, 2027TBA | $42.43M | $-0.15 | $0.00 | 0.01 | -1.25 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
